Chirality Dependent Potency Enhancement and Structural Impact of Glycol Nucleic Acid Modification on siRNA
Mark K. Schlegel(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Donald J. Foster(Alnylam Pharmaceuticals (United States)), Joel M. Harp(Vanderbilt University), Muthusamy Jayaraman(Forma Therapeutics (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Ivan Zlatev(Alnylam Pharmaceuticals (United States)), Jeremy G. Lackey(Alnylam Pharmaceuticals (United States)), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Alexander V. Kel’in(Alnylam Pharmaceuticals (United States)), Martin Egli(Vanderbilt University), Anna Bisbe(Alnylam Pharmaceuticals (United States)), Klaus Charissé(Alnylam Pharmaceuticals (United States)), Pradeep S. Pallan(Vanderbilt University)
Cited by 91
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
|Nature Biotechnology|2008|1.2k